Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There are only two days when I care about share prices. These are the day (or days) when I chose to buy shares, and the day (or days) when I chose to sell them.
Your comparison here to a stock split doubling my share value is nonsense. Thanks for 'participating in the conversation' though.
Their relatively small dilution this week did not do a thing to my actual cost per share
Agreed…do we know how long these new shares are locked up from them being able to sell?
Tell that to the 2.90 buyers the day before
Tell that to the 2.90 buyers the day before
They just killed the company for the next 6 months
They just killed the company for the next 6 months , gave up 50 million in market cap for 5 million funds lol great deal for shareholders lol
A couple of weeks ago the share price was $2 or less. I'm guessing that $2 is what price that CVM could negotiate with whomever big-wig was willing to fork over that much operating capital. It's not the company's focus to maintain a particular share price for short-term traders or newly acquired shareholders looking for a quick score.
It's the company's focus to get Multikine to market, to start generating regular revenue on its own, or to attract interest from a big partner or buy-out pharma. To do that the company needed a sizable chunk of operating capital to keep moving forward. The price to the company for that new chunk of operating capital was a discount for the big investor who could provide that needed capital in the near term.
I bought some new shares this morning at around $2.30. Yeah, sure, they are down even a bit more since then, but I don't focus any money I invest in short-term gains/losses. When Multikine gains regulatory approval - be that in the EU, Great Britain, Canada or with the FDA - that resulting gain in share prices is going to be extremely substantial. Ditto with a buyout - if that's what ends up happening.
How does that recent Warren Buffett quote go: "The stock market is a device for transferring money from the impatient to the patient."
Well, that will keep it from breaking through resistance levels.
Why price it 33% under market , they just killed market
This Offering was to a Single Buyer pursuant to their S-3 Filing of July 2022.
From CEL-SCI Website:
CEL-SCI today announced the pricing of an offering of 2,490,000 shares of its common stock to a single investor at an offering price of $2.00 per share, for gross proceeds of approximately $5 million.
SEC S-3 Filing States:
CEL-SCI Corporation may offer from time to time shares of common stock, preferred stock, convertible preferred stock, rights, warrants, units consisting of one or more of these securities, as well as any of these securities issuable upon conversion of preferred stock or upon the exercise of warrants, at an initial offering price not to exceed $150,000,000, at prices and on terms to be determined at or prior to the time of sale in light of market conditions at the time of sale.
Specific terms pertaining to the securities offered by this prospectus will be set forth in one or more accompanying prospectus supplements, together with the terms of the offering and the initial price and the net proceeds to CEL-SCI from the sale. The prospectus supplement will set forth, without limitation, the terms of the offering and sale of such securities.
CEL-SCI may sell the securities offered by this prospectus directly, through agents designated from time to time, or through underwriters or dealers. If any agents of CEL-SCI or any underwriters or dealers are involved in the sale of the securities, the names of the agents, underwriters or dealers, any applicable commissions and discounts, and the net proceeds to CEL-SCI will be set forth in the applicable prospectus supplement.
A bit of dilution - but not much compared to the total number of shares. We all kind of figured that something like this was going to happen and I think that the market is just doing it's usual bit of overreacting.
We'll see how this plays out today and Friday as the market digests this happening.
CVM: CEL-SCI prices $5M offering of common stock at $2.00 per share
Stalker?? I just cut and pasted what you JUST stated.....on THIS board.
I'm sure that word means what you think it means.
Another day of solid volume and trending upward,... I could get very used to this trend.
LOL and I am called a stalker...
But now I accumulated FBIO instead which is in a better position than Cel these days. Strong pipeline finally.
Got it. Well soon after the r/s my shares were worthless anyways LOL. Everyone just started dumping shares and I went from over $900 worth down to $14.00
I meant the January options
I bought them when they were worthless back in 2008 or so. Still down over $700 even though I bought more in the $1.00 range. I have 50 shares now up from only 7 shares after that massive R/S back in the day. I almost gave up on them. But now I accumulated FBIO instead which is in a better position than Cel these days. Strong pipeline finally.
I wish I'd bought more when they were nearly worthless
Those January 2's are doing VERY well...and another thanks for the reminder
Cel-Sci kicking butt today, up over 25%….
Do we have any moderators on this site? Let’s stick to CVM please?
you did it again....is this intentional??
Let me try again. I am asking if you think the results ( I.e. 5 year survival data ) Cvm is showing not of critical importance until a peer reviewed article is written or at least verified by a third party
No, I’m stating do you think the results they posted
I don't know what that means.
Are you stating, if they say they plan to do something, is the same as them actually doing something?? If so then yes, it is different.
Real companies don't put out PR's on something they plan to do in the future.
So anything they have in print is in your opinion is no results?
Where did I start it?
FWIW, they STILL have no results. They "plan to".
If they have dilute the stock to nil to pay their bills, it's not gonna matter if they invented Penicillin.
Who knows? The stock price is currently above its first resistance. Lets see what happens next.
Next resistance currently $6.73
So they allowed themselves to get into a death financing deal. I guess they blew enough smoke up shareholders butts to keep the stock price while the financial people sold. I don’t know if they had much choice. Unless they were willing to do a merger/buyout for Pennie’s. But back then they had no results. Now they do and the landscape has changed. It’s simple either you believe the results or you don’t. If/when financing comes it will be on the heels of another press release of some sort. I’m not into name calling but you started it
I would NEVER buy Bitcoin. I'd be better off buying Pet Rocks as, at least I could hold those in my hand.
I have been gifted quite a few Plus1 coins from this website and well....,you can look at how well those have done.
In truth, they don't know who started Bitcoin. They credit Satoshi Nakamoto, but that's only a fake name. They also don't know how many exist and the government claim they can't track them if stolen, but that has been proven to be false.
The reason people ask me to look at their companies on here, is because
A) they know I just buy real companies
B) I have zero motivation to lie to them
C) I've been right so stinkin' often.
LOL!!!
So let’s focus on financing that happened years ago because that’s a lot easier then focusing on what would or can be. Any moron can do that.
How the F would I know that.
CEL-SCI’s plan to file for immediate regulatory approval
You should invest in bitcoin. You seem to be knowledgeable enough. Bitcoin was started by the elites / Sea Eye Aye to circumvent CP and human trafficking laws around the world. Which in fact is the largest industry on the planet, surpassing the drug trade by leaps and bounds. Bitcoin Servers are run from the Three Gorges Dam in China. One event or keystroke will wipe it all out like it never existed. Imaginary coin that does not even exist physically. Worse than fiat. Unlike precious metals. But be warned that owning bitcoin is supporting all that evil by default.
How the F would I know that. Financing or not I’m not a short term player like you. All I know is 145,000 would benefit from this. The results are what is exciting. It’s very easy to paint a negative picture. I mean there are a 1000 ways to mess it up. You are just focusing on one of those 1000 ways. And since you’re a newbie to this with not much interest. I would suggest you look at the results of the trial one more time
LOL...have you done it?
Quick! Tell me where they're getting their financing and the structure of the deal?!
So let’s focus on financing that happened years ago because that’s a lot easier then focusing on what would or can be. Any moron can do that.
The company WAS when I looked into it (as someone had asked me to) several years ago....or I guess I will say they were doing finance deals with a company investigated for it. I'm not interested enough to research again, but I don't ever recall seeing a company escape from it.
How would you explain the tanking in share price here?
Of course this is almost never a good thing
About 647,000 results (0.48 seconds)
CVM's third split took place on June 15, 2017. This was a 1 for 25 reverse split, meaning for each 25 shares of CVM owned pre-split, the shareholder now owned 1 share. For example, a 10 share position pre-split, became a 0.4 share position following the split.
One CVM share bought prior to May 1st, 1995 would equal to 0.0004 CVM shares today.
So you’re saying the company is involved with toxic financing?
What are your thoughts on this opinion?
in all actuality couldn't the shorting entities be exactly the same ones that offered the toxic financing?
1) finance toxic stock offering incl loads of warrants
2) actively short stock with warrants as your backstop hedge
3) offer more toxic financing since your market cap sucks now
4) rinse + repeat
I couldn't say. I am or I WAS warning people about the toxic finance deals the company is involved with.
Not sure if you are aware, but once those shares are issued, there is no financial gain to the company as they are being traded.
I'm not a doctor, nor pharma person, so (unlike many here), I'm not willing to offer opinion on that which I have no knowledge.
I do understand investing though.....and outed many a penny stock scam.
Therefore, any argument that I am hurting any actual research being done is quite moot.
I just LOVE the fact that people who claim to have me on ignore, also claim I'm telling lies.....when in fact, all I did was look into the company's filing.
Since when did wearing blinders become an investment strategy?
Oh. You’re trying to assist other investors from not investing in Cvm. So at this point you don’t believe that 145,000 people a year could not be helped by taking multikine?
He/she uses that same tactic that the public serpents and public screw-alls use at all times. Tell a lie enough times and it becomes the truth. Where did I hear that before ? Oh yeah out of the mouth of Goebbels. Ministry of propaganda. We saw its recent deployment in early 2020 as the boogeyman called CLOVID that never existed.
Just one more thing in a list of many that you have no understanding of.
Your stock hit the resistance and fell back. Shouldn't you be finding other things to worry about than my vocabulary? That's right, you have no knowledge of investing.
Quite frequently?? I'm about a hundred less posts than you, and unlike you, I've discussed the financials of the company, where you've just attacked other posters.
Here's a thought, you stop attacking me and I won't have to come on here to explain why you are wrong. Win win.
You have to understand that his goal is to get your attention. If you respond to him then he knows he’s got it
seems you're using the word 'unbiased' incorrectly
Cel-Sci Corporation (CVM)
https://www.youtube.com/watch?v=auAihG3rtC4
Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.
Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.CANCER - MULTIKINE
Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties. More...INFECTIOUS DISEASES - L.E.A.P.S.(TM)**
L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.
This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform. More...* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.
** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products
Partnering Philosophy & Corporate Partners
CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of:
CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.
Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.
CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.
Current Corporate Partners:
a. | Agreement Signed August 2008 | ||
b. | Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011. | ||
c. | Revenue Share | ||
d. | Website - http://www.tevapharm.com/ |
a. | Agreement Signed November 2000 | ||
b. | Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008. | ||
c. | Revenue Share | ||
d. | Website - http://www.oep.com.tw/ |
a. | Agreement signed August 2011 | ||
b. | Territory - Argentina and Venezuela | ||
c. | Revenue Share | ||
d. | Website - http://www.gp-pharm.com/ |
Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology. The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.
* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.
** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.
http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833http://stockcharts.com/freecharts/gallery.html?CVM
http://finance.yahoo.com/q?s=cvm&ql=1
https://frugalnorwegian.com/cvm Insight into CVM P3 Trial Results
https://www.cvmresearch.com Insight into CVM P3 Trial Results & FDA Chances of Approval
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |